Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Mar;9(2):151-8.
doi: 10.1007/BF00916943.

Proliferation of highly purified T cells in response to signaling via surface receptors requires cell-cell contact

Affiliations

Proliferation of highly purified T cells in response to signaling via surface receptors requires cell-cell contact

D Schwartz et al. J Clin Immunol. 1989 Mar.

Abstract

Lymphocyte proliferation is associated with cell-cell aggregation. In order to assess the importance of cell-cell contact in T-cell proliferation we examined the effect of disruption of cellular aggregation by anti LFA-1(4) mAb on T-cell proliferation. Monocyte-dependent T-cell proliferation induced by anti-CD3 mAb, pairs of anti-CD2 mAbs, or PHA was inhibited by anti-LFA-1 mAb. Monocyte-independent proliferation of highly purified T cells to anti-CD3 mAb plus PMA or plus IL-2 and to PHA plus IL-2 was, surprisingly, also inhibited by anti-LFA-1 mAb. Anti-LFA-1 mAb caused the partial inhibition of both low-affinity and high-affinity IL-2 receptor and the complete inhibition of IL-2 synthesis. In contrast to the above, the proliferation of highly purified T cells to PMA plus ionomycin was not inhibited by anti-LFA-1 mAb. These results suggest that optimal activation of highly purified T cells via cell surface receptors requires LFA-1-dependent cell-to-cell contact between proliferating T cells as well as between T cells and accessory cells. Such contact appears to be crucial for initiating IL-2 production and for optimal action of IL-2 through its receptor.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Immunol. 1984 Dec;133(6):3054-61 - PubMed
    1. J Immunol. 1985 Aug;135(2):1020-5 - PubMed
    1. Eur J Immunol. 1985 Sep;15(9):888-92 - PubMed
    1. Eur J Immunol. 1986 Jul;16(7):847-50 - PubMed
    1. J Immunol. 1985 Jan;134(1):70-7 - PubMed

Publication types